TB-500 Research

Malinda KM, Goldstein AL, Kleinman HK

The foundational study establishing Thymosin Beta-4 (the parent molecule of TB-500) as a potent wound healing factor. In a rat full-thickness wound model, Thymosin Beta-4 administered topically or systemically increased wound re-epithelialization by 42% at day 4 and 61% at day 7 compared to saline controls. Treated wounds also contracted at least 11% more than controls. The researchers found that even tiny concentrations (as little as 10 picograms) stimulated keratinocyte migration up to 300% above baseline in the Boyden chamber assay. This was the paper that first characterized Thymosin Beta-4 as a multi-activity wound healing compound with clinical potential.

Goldstein AL, Hannappel E, Kleinman HK

A landmark review establishing the scientific foundation for Thymosin Beta-4 clinical development. The paper documents the peptide’s multiple mechanisms — actin sequestration promoting cell migration, stem/progenitor cell mobilization to injury sites, angiogenesis stimulation, anti-inflammatory modulation, and reduction of myofibroblast activity (which reduces scarring). The review notes that these properties provide the scientific rationale for clinical trials in dermal wounds, corneal injuries, cardiac tissue regeneration after ischemic insult, and CNS trauma recovery. This review remains one of the most cited foundational papers for TB-500 research.

Hara T, et al.

This study specifically examined Thymosin Beta-4’s role in skeletal muscle regeneration — directly relevant to TB-500’s applications in sports recovery research. The researchers found that Tβ4 mRNA was upregulated in regenerating muscle fibers following injury, and that both Tβ4 and its sulphoxidized form significantly accelerated wound closure and increased chemotaxis (directed migration) of muscle progenitor cells (myoblasts) toward the injury site. The study established that Thymosin Beta-4 is not just a passive wound healing molecule but an active recruiter of the cells needed to rebuild damaged muscle tissue.

Maar K, et al.

A compelling 2021 review examining Thymosin Beta-4’s regenerative potential from a developmental biology perspective. The paper documents how Tβ4 is expressed at high levels during embryonic development across the heart, brain, limb buds, and muscles — and how supplementing adult tissue with Tβ4 may reactivate these developmental repair programs. It covers TB-500’s anti-inflammatory mechanism (blocking neutrophil chemotaxis, reducing cytochrome c release, decreasing caspase activation), its role in cardiac regeneration after ischemia, corneal wound healing, and its potential as an anti-aging therapeutic. The paper also acknowledges ongoing research into TB-500’s use as a performance-enhancing compound in sports.

PMC Research Group

A 2025 review placing TB-500 in the broader context of therapeutic peptides for orthopaedic injuries. The paper summarizes TB-500’s mechanisms — actin polymerization promotion, progenitor cell recruitment, enhanced cellular migration, anti-inflammatory effects, and proangiogenic activity — and notes its parallels with BPC-157 in terms of tissue repair mechanisms. The review identifies TB-500 as one of several emerging peptides with potential for tendon and muscle repair applications, while acknowledging that formal clinical evidence in humans remains limited and that these compounds are being used ahead of regulatory approval.